HOOKIPA Pharma

Historical price data

HOOKIPA Pharma's mission is to develop novel immunotherapies that reprogram the immune system to combat cancer and infectious diseases. Its core achievement is the development of a proprietary, replicating arenavirus vector platform (VaxWave®/TheraT®) designed to elicit superior antigen-specific CD8+ T cell responses, a strategy validated by foundational Nobel Prize-winning science. The company's strategy focuses on advancing a clinical-stage pipeline in high-unmet-need areas like HPV16+ cancers and cytomegalovirus (CMV) while exploring partnerships to leverage its versatile platform technology.

Proprietary replicating arenavirus vector platform (VaxWave®/TheraT®) engineered to elicit potent and durable antigen-specific CD8+ T cell and antibody responses.

Faces intense competition in both oncology (from other immunotherapies and targeted therapies) and infectious diseases (from large vaccine developers). Differentiation hinges on the platform's ability to generate superior CD8+ T cell responses.